CSF2 and pachyonychia congenita: In that phase I study, a poxvirus targeting CEA and MUC-1 along with B7.1, ICAM-1 and LFA-3 (TRICOM) (PANVAC-V) was administered followed by booster vaccinations using PANVAC-F (fowlpox virus with same antigens) as well as GM-CSF in ten advanced PC patients.